Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FT 596 (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Fate Therapeutics

    • Most Recent Events

    • 18 Nov 2024 According to a Fate Therapeutics media release, data from this trial were presented at the American College of Rheumatology (ACR) Convergence being held in Washington, D.C
    • 18 Nov 2024 Results presented in the Fate Therapeutics Media Release.
    • 25 Oct 2023 Status changed from active, no longer recruiting to discontinued. The study was terminated by the Sponsor.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top